Description:
This Window Of Opportunity clinical trial will examine the immunologic effects of the study
agent HB-201 in the head and neck or cervical cancer, when administered either by IT
injection or by IV route.
Title
- Brief Title: A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer
- Official Title: A Phase 0 Trial of HB-201 for Subjects With Transoral Resectable Human Papillomavirus 16 Positive (HPV 16+) Oropharynx Cancer or With Locally Advanced Cervical Cancer Treated With Chemotherapy and Radiation
Clinical Trial IDs
- ORG STUDY ID:
H-200-002
- NCT ID:
NCT04630353
Conditions
- HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer
Interventions
Drug | Synonyms | Arms |
---|
HB-201 IT | | HB-201 Intratumorally on Day 1 |
HB-201 IV | | HB-201 Intravenously on Day 1 |
HB-201 IT | | HB-201 Intratumorally 7 to 14 days before chemoradiation |
Purpose
This Window Of Opportunity clinical trial will examine the immunologic effects of the study
agent HB-201 in the head and neck or cervical cancer, when administered either by IT
injection or by IV route.
Detailed Description
The window of opportunity, Study H-200-002, will examine the effects of study agent (HB-201)
on subjects during the "window" between diagnosis of their cancer and their definitive cancer
surgery or chemoradiation.
The study will be a 2-arm study design. In Arm 1, the study will enroll subjects with
resectable stage I-III human papillomavirus 16 positive (HPV 16+) genotype squamous cell
cancer of the oropharynx who are candidates for transoral surgery. Participants will receive
a single dose of the study agent HB-201 prior to transoral surgery. Arm 1 will consist of 2
Cohort groups; Cohort 1 will enroll subjects receiving HB-201 as an intratumoral injection
and Cohort 2 will enroll patients receiving HB-201 administered intravenously.
In Arm 2, the study will enroll cervical cancer subjects who have locally advanced squamous
cell carcinoma, adenocarcinoma, and/ or adenosquamous cell carcinoma with HPV 16+ genotype.
Subjects with advanced/metastatic disease that are previously untreated who are planning to
undergo upfront chemoradiation for local control are eligible and will receive an
intratumoral injection of HB-201 prior to the start of chemoradiation.
Trial Arms
Name | Type | Description | Interventions |
---|
HB-201 Intratumorally on Day 1 | Experimental | Patients with resectable stage I-III, HPV 16+ genotype squamous cell cancer of the oropharynx. | |
HB-201 Intravenously on Day 1 | Experimental | Patients with resectable stage I-III, HPV 16+ genotype squamous cell cancer of the oropharynx. | |
HB-201 Intratumorally 7 to 14 days before chemoradiation | Experimental | Patients with cervical cancer who have locally advanced squamous cell carcinoma with HPV 16+ genotype. | |
Eligibility Criteria
Inclusion Criteria:
All subjects:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Confirmed HPV 16+ (human papilloma virus 16 positive) genotype testing of cancer.
- Disease-free for ≥ 2 years from other curatively treated cancers, with
protocol-defined exceptions.
- Evaluated by cardiologist and/or neurologist if protocol-defined cardiac or
neurological event within the last 6 months.
HPV 16+ Oropharynx Cancer (Arm 1 Cohorts 1 and 2)
- Newly diagnosed, squamous cell carcinoma or undifferentiated carcinoma of the
oropharynx, determined to be resectable.
- AJCC v8.0 Tumor, Node, Metastasis (TNM) stage I-III, cT1- T3, and cervical nodes N1-N3
based on clinical or radiographic criteria with no evidence of distant metastases.
- No prior radiation above the clavicles.
- Must have acceptable renal and hepatic function as defined per protocol.
- Cohort 2 (intratumoral administration) only: must have a safe and accessible tumor
lesion amenable for biopsy and IT administration.
HPV 16+ Cervical Cancer (Arm 2)
- Newly diagnosed, histologically confirmed advanced cervical cancer (squamous cell
carcinoma, adenocarcinoma, or adenosquamous cell carcinoma): International Federation
of Gynecology and Obstetrics (FIGO) clinical stages IB to IVB with plan for initial
treatment of definitive chemoradiation (platinum agent weekly with radiotherapy) for
either curative intent or control of local (pelvic) disease.
- No prior radiation to the abdomen or pelvis.
- Must have a safe and accessible tumor lesion amenable for biopsy and IT
administration.
- Must have normal organ and marrow function as defined per protocol.
- Must not have a known allergy to cisplatin, carboplatin, or compounds of similar
biologic composition.
Exclusion Criteria:
All subjects:
- Treatment with any systemic anticancer therapy within 3 years (unless agreed otherwise
between the Sponsor and the Investigator).
- Treatment with any chronic immunosuppressive medication within 6 months (unless agreed
otherwise between the Sponsor and Investigator).
- Uncontrolled diabetes, uncontrolled infection despite antibiotics or uncontrolled
hypertension.
- Live vaccine within 28 days (unless agreed otherwise between Sponsor and
Investigator).
- Known diagnosis of acquired immunodeficiency syndrome (AIDS).
- Positive Hepatitis B or Hepatitis C tests indicating acute or chronic infection.
- Intercurrent illness likely to interfere with protocol therapy.
- Female subjects who are pregnant or breastfeeding.
- Female subjects of childbearing potential who do not agree to the use of highly
effective contraception per protocol.
- Male subjects with sexual partners of childbearing potential who do not agree to the
use of protocol-defined contraception
HPV 16+ Oropharynx Cancer (Arm 1 Cohorts 1 and 2)
• Primary tumor or nodal metastasis fixed to the carotid artery, skull base, or cervical
spine.
HPV 16+ Cervical Cancer (Arm 2)
- Treatment with chemotherapy for cervical cancer, prior to planned chemoradiation.
- Prior allogeneic bone marrow transplantation or prior solid organ transplantation.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Immune response profiles in subjects with HPV 16+ Head and Neck and cervical cancer. |
Time Frame: | Approximately 6-8 weeks |
Safety Issue: | |
Description: | Measurement of antigen-specific CD8+ T cells in blood and tissue (E7E6 antigen specific assay). |
Secondary Outcome Measures
Measure: | Measurement of messenger RNA and expression profiles in tumor specimens using RNA-sequencing (800 genes). |
Time Frame: | Approximately 6-8 weeks |
Safety Issue: | |
Description: | Pre and post administration of HB-201 |
Measure: | Assessment of tumor mutational burden (TMB, MSI) in tumor specimens using whole exome sequencing. |
Time Frame: | Approximately 6-8 weeks |
Safety Issue: | |
Description: | Pre and post administration of HB-201 |
Measure: | Measure TH1/TH2 proinflammatory cytokines (mesoscale multiplex discovery assay) to characterize metabolic / proteomic changes in serum / plasma |
Time Frame: | Approximately 6-8 weeks |
Safety Issue: | |
Description: | Pre and post administration of HB-201 |
Measure: | Measure ctDNA to characterize changes in circulating tumor by NextGen sequencing. |
Time Frame: | Approximately 6-8 weeks |
Safety Issue: | |
Description: | Pre and post administration of HB-201 |
Measure: | Characterize t-cell receptor repertoire diversity and clonality, by t-cell receptor sequencing. |
Time Frame: | Approximately 6-8 weeks |
Safety Issue: | |
Description: | Pre and post administration of HB-201. |
Measure: | Clinical evidence of response to HB-201 |
Time Frame: | Approximately 6-8 weeks |
Safety Issue: | |
Description: | Change in tumor size per RECIST v1.1 |
Measure: | Toxicity profile of HB-201 |
Time Frame: | Approximately 30 days post HB-201 administration |
Safety Issue: | |
Description: | Number and type of adverse events per CTCAE v5.0 |
Details
Phase: | Early Phase 1 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Hookipa Biotech GmbH |
Trial Keywords
- HPV
- Oropharynx Cancer
- Cervical Cancer
- Intratumoral
- Intravenous
- Lymphocytic Choriomeningitis Virus
- Medical College of Wisconsin Cancer Center
- Medical College of Wisconsin
- Transoral Surgery
- Window of Opportunity
- HPV 16+
- HPV 16+ head and neck squamous cell cancer
- HPV 16 E7E6
- E7E6
Last Updated
August 16, 2021